Foundational guide
Selank Dosage: What a Dose Would Require
This is the rare case where an authorised dose exists somewhere. Tracing what it is attached to explains why it cannot be lifted out and used elsewhere.
Selank dosage is an unusual case among research peptides, because a number genuinely exists somewhere. This compound is a registered medicine in Russia, and an authorised product has an approved dose attached to it. What that number cannot do is travel.
This article states no quantity and gives no administration guidance. It works through what an approved dose is attached to, why detaching it destroys its meaning, and what the Western published record contains, which is close to nothing.
Supplier publishing lot-level data
Selank, Ascension Peptides
Every lot carries certificates from two independent laboratories. The code below halves the listed price on the vial.
The published certificate for lot 29-01260229 assays this vial at 12.29 mg against a 10 mg label, and reports no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Kovera Labs and MZ Biolabs certificates per lot
- Carriage free above $250
- Dispatched same day before 2pm CST
Supplied for laboratory research use and not for human consumption. Affiliate links: a commission may be earned at no cost to the reader, and it does not affect the assessment above. Prices verified August 21, 2026.
The number exists, and it does not travel
An approved dose is not a property of a molecule. It is a property of a product: a specific formulation, at a specific concentration, delivered by a specified route, manufactured to a specification, assessed for a stated indication in a defined population, and administered under supervision by someone who screened the patient first.
Every one of those is load bearing. Change the formulation and the exposure changes. Change the route and the exposure changes, often by a large factor. Change the population and the risk balance that justified the dose changes. Change the manufacturer to one with no release testing and the relationship between the label and the contents becomes an assumption rather than a specification.
A number lifted out of an approved labelling and applied to research chemical material bought online has been detached from all six. It looks like the same number and refers to a different thing, which is why a Selank dosage quoted online and an approved dose can share every digit and no meaning.
What the parent regulatory judgement covered
The compound is a synthetic heptapeptide derived from tuftsin, an endogenous peptide, developed in Russia and studied there principally as an anxiolytic. Its registration means a regulator reviewed a dossier covering manufacture, quality control, preclinical work and clinical data, and permitted sale for a stated indication.
That is a real institutional judgement based on real evidence, and dismissing it as nonexistent is wrong. It is also not equivalent to a Western registration trial, and the distinction is not about quality but about access and convention: the dossier is generally not retrievable by a reader outside the system, and much of the supporting literature is published in Russian in journals not comprehensively indexed in the databases most readers search.
The consequence for a dosing question is specific. The evidence behind the approved number cannot be inspected by the person quoting it, which means the person quoting it cannot say what population it applied to, what outcome justified it, or how the boundaries were established. Citing a number whose derivation you cannot see is not the same as citing evidence.
Route is part of the specification
The Russian product is a nasal formulation, and that is not a detail to skim past.
Peptides are generally susceptible to enzymatic degradation and are cleared quickly, which is why the fraction of an administered quantity that reaches circulation differs sharply between routes. A mass delivered nasally, a mass delivered by injection and a mass swallowed are three different exposures. Formulation compounds the problem further: buffer, concentration and excipients affect both stability and absorption, which is why an authorised product specifies all of them rather than a mass alone.
Figures circulating in English are typically bare masses, stripped of route, formulation and concentration. That makes them underdetermined before anyone even asks whether evidence supports them.
What the Western published record contains
Very little, and it is worth being precise about the shape of the gap.
There is no Western marketing authorisation: no FDA, EMA or MHRA approval. There is no genuine registered Western trial, and no trial registry identifier should be cited for this compound in either direction. There is no published Western human pharmacokinetic profile, so absorption and clearance figures that a schedule could be derived from are not available. And there is no published Western dose ranging study comparing exposures against outcomes.
Anyone checking this in a registry will meet a trap that catches almost everyone. A keyword search matches text anywhere in a record, so a search returns interventional studies with no connection to the compound: an antiseizure drug in epilepsy, transcranial stimulation for dyslexia, telephone delivered psychotherapy for depression, neurofeedback training, balance exercises. Reading the titles is what exposes this. A count taken from the search field, without opening the records, describes a text index rather than a literature, and quoting such a count is the most common way writing about this compound goes wrong.
Selank dosage: what fixes a number, and what does not
| Requirement | Authorised product in its own jurisdiction | Research chemical material bought online |
|---|---|---|
| Reviewed clinical dossier | Yes, assessed by a national regulator | None |
| Stated indication and population | Yes | None; use is self directed |
| Fixed route and formulation | Yes, specified in the authorisation | Chosen by the user, often differing from the approved route |
| Batch release testing of identity and content | Required | Not required |
| Sterility and endotoxin control | Required for the approved presentation | Not required |
| Stability data behind storage and expiry | Generated during development | Absent; storage advice is convention |
| Prescriber screening and supervision | Yes | No |
| Publicly inspectable derivation of the number | Generally not, from outside that system | Not applicable |
The last row is the one that surprises readers, and it is why this compound sits awkwardly in both directions. Even the number that does exist cannot be checked by most people who cite it, and the material most readers would apply it to fails every requirement above it.
Self directed dose finding, and why this outcome defeats it
People who cannot find an evidence based number often fall back on adjusting until something happens. For a compound with an objective readout, that at least produces a signal, even if an uncontrolled one. For an anxiolytic it does not.
Anxiety is assessed with rating scales completed by a person or administered by a clinician, which means the readout is a judgement rather than an instrument value. Inside a blinded trial that is workable, because neither the participant nor the assessor knows the allocation. Outside one, the readout carries the expectation with it, and expectation moves reported anxiety reliably enough that trials in this field are designed around the effect rather than treating it as background noise.
So a person adjusting an unverified quantity of unverified material against their own impression of their own anxiety is running a search whose feedback signal responds to the act of searching. Whatever number that process settles on is a record of the process, not a property of the compound, and it will feel well founded to the person who arrived at it.
Where circulating figures come from
Trace a figure quoted in English and it usually resolves into one of four origins. A quantity from the approved product, restated without route, formulation, indication or supervision. A vendor's suggestion, which is a commercial decision. A forum consensus, which is the average of other people's guesses and drifts with repetition. Or an extrapolation from a different peptide on the reasoning that similar molecules behave similarly, which is unreliable even within one peptide family.
Only the first has any relationship to evidence, and the relationship is severed by the stripping. Repetition across many pages does not improve any of them. It changes how established they look, and search results reward the appearance rather than the origin.
Frequently asked questions
- Is there an established Selank dosage?
- There is an approved dose for an authorised product in Russia, attached to a formulation, a route, an indication and a supervised setting. There is no established dose for research chemical material used outside that context, and no published Western dose ranging data.
- Can the approved figure be used with material bought online?
- The two situations share a molecule name and nothing else that determines exposure: not the formulation, not the concentration, not the route in most cases, and not any assurance that the vial contains what the label claims.
- Why is the route emphasised so heavily?
- Because the fraction of an administered quantity reaching circulation depends on it, sometimes by a large factor. A mass without a route is not a dose, it is a number.
- Do rodent studies indicate a human quantity?
- No. Converting an animal administration level into a human one requires human pharmacokinetic data to anchor the scaling, and none has been published in the Western literature for this compound.
- What would produce a checkable answer outside Russia?
- Published human pharmacokinetics, a dose ranging study with more than one arm, a pre registered randomised trial reporting a pre specified outcome, and a product with release testing behind it. None of those currently exists.
Limitations of the evidence
This page prints no administration guidance and no quantity a reader could act on. Any figure attached to this compound outside Russia is a number without an authorising document behind it. Selank is registered as a medicine in Russia, which means a national regulator reviewed a dossier and permitted sale for a stated indication. It holds no FDA, EMA or MHRA authorisation, no published Western registration trial exists, and no trial registry identifier can honestly be cited for it. Much of the underlying clinical literature is published in Russian in journals that are not comprehensively indexed in English language databases, so a reader outside Russia often cannot inspect the study behind a claim. Nothing here describes or recommends human use.